Central Pacific Bank Trust Division Invests $131,000 in United Therapeutics Co. (NASDAQ:UTHR)

Central Pacific Bank Trust Division acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 575 shares of the biotechnology company’s stock, valued at approximately $131,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rise Advisors LLC acquired a new stake in shares of United Therapeutics during the 1st quarter worth approximately $32,000. GAMMA Investing LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $43,000. Benjamin F. Edwards & Company Inc. grew its stake in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 117 shares during the period. Janiczek Wealth Management LLC grew its stake in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares during the period. Finally, Blue Trust Inc. grew its stake in United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.8 %

Shares of NASDAQ UTHR traded up $2.63 during trading on Wednesday, hitting $325.28. 41,601 shares of the company were exchanged, compared to its average volume of 494,258. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $326.46. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The company has a fifty day moving average price of $286.06 and a 200-day moving average price of $247.91. The firm has a market capitalization of $14.43 billion, a PE ratio of 15.26, a P/E/G ratio of 1.39 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the firm earned $4.86 EPS. As a group, equities research analysts expect that United Therapeutics Co. will post 24.73 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on UTHR shares. Oppenheimer lifted their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. HC Wainwright reissued a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. UBS Group lifted their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. Finally, Wells Fargo & Company lifted their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $318.00.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total value of $84,742.28. Following the sale, the director now directly owns 5,107 shares in the company, valued at approximately $1,626,988.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total value of $84,742.28. Following the sale, the director now directly owns 5,107 shares in the company, valued at approximately $1,626,988.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $235.42, for a total transaction of $847,512.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $30,604.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,884 shares of company stock worth $27,604,643. Company insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.